Vincerx Pharma, Inc. (VINC): Price and Financial Metrics


Vincerx Pharma, Inc. (VINC): $1.28

-0.05 (-3.76%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add VINC to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

VINC Stock Price Chart Interactive Chart >

Price chart for VINC

VINC Price/Volume Stats

Current price $1.28 52-week high $8.03
Prev. close $1.33 52-week low $0.63
Day low $1.24 Volume 101,800
Day high $1.34 Avg. volume 87,578
50-day MA $0.90 Dividend yield N/A
200-day MA $1.41 Market Cap 27.12M

Vincerx Pharma, Inc. (VINC) Company Bio


Vincerx Pharma, Inc. operates as a clinical-stage life sciences company. The Company focuses on developing VIP152 inhibits PTEFb phosphorylation of RNA polymerase II (RNAPII), thereby preventing transcription elongation and blocking expression of genes that drive cancer. Vincerx Pharma serves customers worldwide.


VINC Latest News Stream


Event/Time News Detail
Loading, please wait...

VINC Latest Social Stream


Loading social stream, please wait...

View Full VINC Social Stream

Latest VINC News From Around the Web

Below are the latest news stories about VINCERX PHARMA INC that investors may wish to consider to help them evaluate VINC as an investment opportunity.

What Could Change After Vincerx Pharma Inc. (NASDAQ: VINC) Gains 35.71% From The High-Point?

Vincerx Pharma Inc. (NASDAQ:VINC)’s traded shares stood at 0.41 million during the last session. At the close of trading, the stock’s price was $0.98, to imply an increase of 11.41% or $0.1 in intraday trading. The VINC share’s 52-week high remains $10.59, putting it -980.61% down since that peak but still an impressive 35.71% since … What Could Change After Vincerx Pharma Inc. (NASDAQ: VINC) Gains 35.71% From The High-Point? Read More »

Marketing Sentinel | December 24, 2022

Immix, Avidity top healthcare gainers; Vincerx, Yumanity lead losers'' pack

Immix Biopharma (IMMX) +69%. Avidity Biosciences RNA +37%. Vincerx Pharma (VINC) -21%. Yumanity Therapeutics (YMTX) -16%.

Seeking Alpha | December 14, 2022

Vincerx Pharma Announces FDA Safe to Proceed Letter for Investigational New Drug (IND) Application for its αVβ3 Small Molecule-Drug Conjugate (SMDC) VIP236

VIP236 is a first-in-class αVβ3 integrin binder SMDC with the potential to address a broad patient population across multiple solid tumor indications Preclinical studies with VIP236 demonstrated promising tumor regression in in vivo cancer models VIP236 first-in-human study in advanced or metastatic solid tumors anticipated to commence in Q1 2023 PALO ALTO, Calif., Dec. 13, 2022 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet med

Yahoo | December 13, 2022

Vincerx Pharma Provides American Society of Hematology Annual Meeting 2022 Poster Highlights on Enitociclib in Multiple Tumor Types

In a multiple myeloma (MM) preclinical study, antitumor efficacy was observed with enitociclib as a monotherapy and in combination with several anti-MM agents Significant MYC downregulation was observed in patients with double-hit diffuse large B-cell lymphoma (DH-DLBCL) and other B-cell malignancies with a 30-mg dose level while maintaining a favorable safety profile Clinical trial to evaluate enitociclib in combination with venetoclax and prednisone (NIH sponsored) anticipated to commence in Q

Yahoo | December 12, 2022

Vincerx Pharma Presents Preclinical Data on VIP943 in Acute Myeloid Leukemia Models at the 64th American Society of Hematology Annual Meeting 2022

Vincerx’s proprietary payload and linker technology and VIP943, a novel anti-CD123 antibody drug conjugate (ADC), demonstrated superiority with significant improved safety in non-human primates (NHP) when compared with Mylotarg™ (gemtuzumab ozogamicin) VIP943 demonstrated monotherapy activity in ex vivo AML models and in vivo activity with significant tumor regression in combination with venetoclax and azacitidine in an acute myeloid leukemia (AML) mouse model VIP943 IND-enabling studies continu

Yahoo | December 11, 2022

Read More 'VINC' Stories Here

VINC Price Returns

1-mo 23.08%
3-mo 19.63%
6-mo -7.25%
1-year -81.18%
3-year N/A
5-year N/A
YTD 25.49%
2022 -89.99%
2021 -51.27%
2020 N/A
2019 N/A
2018 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.627 seconds.